Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial

Review Emergency Medicine

Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: A systematic review and meta-analysis

Baris Gungor et al.

Summary: This study found that elevated D-dimer levels on admission are significantly correlated with the severity of COVID-19 pneumonia and may predict mortality in hospitalized patients, indicating it as a potential predictive marker.

AMERICAN JOURNAL OF EMERGENCY MEDICINE (2021)

添加到收藏夹

Review Critical Care Medicine

Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019 A Systematic Review and Meta-analysis

David Jimenez et al.

Summary: The pooled incidence of VTE and bleeding among hospitalized patients with COVID-19 was 17.0% and 7.8% respectively. Factors such as routine screening, critical illness, inclusion of distal DVT and subsegmental PE, and prospective studies were associated with higher rates of VTE. The incidence of bleeding events was sensitive to escalated doses of anticoagulants and the nature of data collection.

CHEST (2021)

添加到收藏夹

Article Hematology

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

Adam Cuker et al.

Summary: The American Society of Hematology provided two conditional recommendations for anticoagulation in COVID-19-related critical illness and acute illness, emphasizing the low certainty in the evidence and the importance of future high-quality randomized controlled trials for validation.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Medicine, General & Internal

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit The INSPIRATION Randomized Clinical Trial

Parham Sadeghipour et al.

Summary: This study compared the effect of intermediate-dose and standard prophylactic anticoagulation on a composite outcome among COVID-19 patients admitted to the ICU. The results showed no significant difference between the two groups in terms of thrombotic events, ECMO therapy, or mortality within 30 days. The study does not recommend routine use of intermediate-dose prophylactic anticoagulation in unselected ICU patients with COVID-19.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulaTlon cOroNavirus)-Coalition IV trial

Renato D. Lopes et al.

Summary: The ACTION trial aims to evaluate whether in-hospital therapeutic anticoagulation with rivaroxaban for stable patients, or enoxaparin for unstable patients, followed by rivaroxaban through 30 days compared with standard prophylactic anticoagulation improves clinical outcomes in hospitalized patients with COVID-19 and elevated D-dimer levels.

AMERICAN HEART JOURNAL (2021)

添加到收藏夹

Review Critical Care Medicine